{"id":37741,"date":"2025-07-22T15:27:02","date_gmt":"2025-07-22T07:27:02","guid":{"rendered":"https:\/\/flcube.com\/?p=37741"},"modified":"2025-07-22T15:27:03","modified_gmt":"2025-07-22T07:27:03","slug":"genentechs-astegolimab-shows-promising-results-in-phase-iib-copd-trial","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=37741","title":{"rendered":"Genentech’s Astegolimab Shows Promising Results in Phase IIb COPD Trial"},"content":{"rendered":"\n

Genentech, a member of the Roche Group (SWX: ROG<\/a>, OTCMKTS: RHHBY<\/a>), announced the results of two key clinical trials evaluating astegolimab in patients with moderate to severe chronic obstructive pulmonary disease (COPD). The Phase IIb ALIENTO study met its primary endpoint, demonstrating a statistically significant reduction in the annualized exacerbation rate (AER). However, the Phase III ARNASA study did not meet its primary endpoint.<\/p>\n\n\n\n

Clinical Trial Outcomes<\/strong>
The ALIENTO trial enrolled 1,301 COPD patients and showed that astegolimab, administered once every two weeks, led to a statistically significant 15.4% reduction in AER over 52 weeks. In contrast, the ARNASA trial enrolled 1,375 patients and observed a 14.5% reduction in AER, which did not reach statistical significance.<\/p>\n\n\n\n

Study Details<\/strong>
Both studies included current or former smokers with a history of frequent exacerbations, regardless of blood eosinophil count. All participants received standard maintenance therapy, including various combinations of inhaled corticosteroids (ICS), long-acting beta agonists (LABA), and long-acting muscarinic antagonists (LAMA). The total number of exacerbation events in both studies was lower than anticipated. The safety profile of astegolimab remained consistent with previous findings, with no new safety concerns identified.<\/p>\n\n\n\n

Drug Mechanism<\/strong>
Astegolimab is an investigational fully human monoclonal antibody targeting the ST2 receptor. It is designed to bind ST2 with high affinity and block IL-33 signaling. Genentech plans to engage with regulatory authorities to discuss the findings and will present full results at upcoming medical conferences.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Genentech, a member of the Roche Group (SWX: ROG, OTCMKTS: RHHBY), announced the results of…<\/p>\n","protected":false},"author":1,"featured_media":37742,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[17,1111,940,939],"class_list":["post-37741","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-results","tag-genentech","tag-otcmkts-rhhby","tag-swx-rop"],"yoast_head":"\nGenentech's Astegolimab Shows Promising Results in Phase IIb COPD Trial - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Genentech, a member of the Roche Group (SWX: ROG, OTCMKTS: RHHBY), announced the results of two key clinical trials evaluating astegolimab in patients with moderate to severe chronic obstructive pulmonary disease (COPD). The Phase IIb ALIENTO study met its primary endpoint, demonstrating a statistically significant reduction in the annualized exacerbation rate (AER). However, the Phase III ARNASA study did not meet its primary endpoint.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=37741\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Genentech's Astegolimab Shows Promising Results in Phase IIb COPD Trial\" \/>\n<meta property=\"og:description\" content=\"Genentech, a member of the Roche Group (SWX: ROG, OTCMKTS: RHHBY), announced the results of two key clinical trials evaluating astegolimab in patients with moderate to severe chronic obstructive pulmonary disease (COPD). The Phase IIb ALIENTO study met its primary endpoint, demonstrating a statistically significant reduction in the annualized exacerbation rate (AER). However, the Phase III ARNASA study did not meet its primary endpoint.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=37741\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-22T07:27:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-22T07:27:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2208.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37741#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37741\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Genentech’s Astegolimab Shows Promising Results in Phase IIb COPD Trial\",\"datePublished\":\"2025-07-22T07:27:02+00:00\",\"dateModified\":\"2025-07-22T07:27:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37741\"},\"wordCount\":244,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37741#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2208.webp\",\"keywords\":[\"Clinical trial results\",\"Genentech\",\"OTCMKTS: RHHBY\",\"SWX: ROP\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37741#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37741\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=37741\",\"name\":\"Genentech's Astegolimab Shows Promising Results in Phase IIb COPD Trial - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37741#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37741#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2208.webp\",\"datePublished\":\"2025-07-22T07:27:02+00:00\",\"dateModified\":\"2025-07-22T07:27:03+00:00\",\"description\":\"Genentech, a member of the Roche Group (SWX: ROG, OTCMKTS: RHHBY), announced the results of two key clinical trials evaluating astegolimab in patients with moderate to severe chronic obstructive pulmonary disease (COPD). The Phase IIb ALIENTO study met its primary endpoint, demonstrating a statistically significant reduction in the annualized exacerbation rate (AER). However, the Phase III ARNASA study did not meet its primary endpoint.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37741#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37741\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37741#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2208.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2208.webp\",\"width\":1080,\"height\":608,\"caption\":\"Genentech's Astegolimab Shows Promising Results in Phase IIb COPD Trial\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37741#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Genentech’s Astegolimab Shows Promising Results in Phase IIb COPD Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Genentech's Astegolimab Shows Promising Results in Phase IIb COPD Trial - Insight, China's Pharmaceutical Industry","description":"Genentech, a member of the Roche Group (SWX: ROG, OTCMKTS: RHHBY), announced the results of two key clinical trials evaluating astegolimab in patients with moderate to severe chronic obstructive pulmonary disease (COPD). The Phase IIb ALIENTO study met its primary endpoint, demonstrating a statistically significant reduction in the annualized exacerbation rate (AER). However, the Phase III ARNASA study did not meet its primary endpoint.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=37741","og_locale":"en_US","og_type":"article","og_title":"Genentech's Astegolimab Shows Promising Results in Phase IIb COPD Trial","og_description":"Genentech, a member of the Roche Group (SWX: ROG, OTCMKTS: RHHBY), announced the results of two key clinical trials evaluating astegolimab in patients with moderate to severe chronic obstructive pulmonary disease (COPD). The Phase IIb ALIENTO study met its primary endpoint, demonstrating a statistically significant reduction in the annualized exacerbation rate (AER). However, the Phase III ARNASA study did not meet its primary endpoint.","og_url":"https:\/\/flcube.com\/?p=37741","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-22T07:27:02+00:00","article_modified_time":"2025-07-22T07:27:03+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2208.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=37741#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=37741"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Genentech’s Astegolimab Shows Promising Results in Phase IIb COPD Trial","datePublished":"2025-07-22T07:27:02+00:00","dateModified":"2025-07-22T07:27:03+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=37741"},"wordCount":244,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=37741#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2208.webp","keywords":["Clinical trial results","Genentech","OTCMKTS: RHHBY","SWX: ROP"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=37741#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=37741","url":"https:\/\/flcube.com\/?p=37741","name":"Genentech's Astegolimab Shows Promising Results in Phase IIb COPD Trial - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=37741#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=37741#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2208.webp","datePublished":"2025-07-22T07:27:02+00:00","dateModified":"2025-07-22T07:27:03+00:00","description":"Genentech, a member of the Roche Group (SWX: ROG, OTCMKTS: RHHBY), announced the results of two key clinical trials evaluating astegolimab in patients with moderate to severe chronic obstructive pulmonary disease (COPD). The Phase IIb ALIENTO study met its primary endpoint, demonstrating a statistically significant reduction in the annualized exacerbation rate (AER). However, the Phase III ARNASA study did not meet its primary endpoint.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=37741#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=37741"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=37741#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2208.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2208.webp","width":1080,"height":608,"caption":"Genentech's Astegolimab Shows Promising Results in Phase IIb COPD Trial"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=37741#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Genentech’s Astegolimab Shows Promising Results in Phase IIb COPD Trial"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2208.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37741","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=37741"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37741\/revisions"}],"predecessor-version":[{"id":37743,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37741\/revisions\/37743"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/37742"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=37741"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=37741"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=37741"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}